Phenotype Standardization for Statin-Induced Myotoxicity

A. Alfirevic*, D. Neely, J. Armitage, H. Chinoy, R. G. Cooper, R. Laaksonen, D. F. Carr, K. M. Bloch, J. Fahy, A. Hanson, Q. Y. Yue, M. Wadelius, A. H. Maitland-van Der Zee, D. Voora, B. M. Psaty, C. N A Palmer, M. Pirmohamed

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.Clinical Pharmacology and Therapeutics (2014); advance online publication 02 July 2014. doi:10.1038/clpt.2014.121.

Original languageEnglish
Pages (from-to)470-476
JournalClinical Pharmacology and Therapeutics
Volume96
Issue number4
DOIs
Publication statusPublished - Oct 2014

Fingerprint

Dive into the research topics of 'Phenotype Standardization for Statin-Induced Myotoxicity'. Together they form a unique fingerprint.

Cite this